Open AccessAn In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
Author(s) -
Amanat Fatima,
White Kris M.,
Miorin Lisa,
Strohmeier Shirin,
McMahon Meagan,
Meade Philip,
Liu WenChun,
Albrecht Randy A.,
Simon Viviana,
MartinezSobrido Luis,
Moran Thomas,
GarcíaSastre Adolfo,
Krammer Florian
Publication year - 2020
Publication title -
current protocols in microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 35
eISSN - 1934-8533
pISSN - 1934-8525
DOI - 10.1002/cpmc.108
Subject(s) - virology , serology , antibody , in vitro , antiviral drug , biology , virus , drug , covid-19 , immunology , coronavirus , pharmacology , medicine , infectious disease (medical specialty) , pathology , biochemistry , disease
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS‐CoV‐2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS‐CoV‐2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1 : Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2 : Screening of anti‐SARS‐CoV‐2 compounds in vitro Support Protocol : SARS‐CoV‐2 propagation